Amarin Corp Plc (AMRN)

[ziploc_1]

The patent on the new emulsified formulation of EPA will make generic substitution an infringment...Generics can still sell gV, but not MD-2119.

I anticipate that the market would eventually phase out Vascepa in favor of MD-2119